PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context‐Dependent Therapeutic Vulnerability
Genes, Chromosomes and Cancer · 2026-07 · 65 (7)
DOI: 10.1002/gcc.70151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 01.07.2026. Verfasst von Lingxi Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Translational Medicine Institute, the Affiliated Chenzhou Hospital, Hengyang Medical School, University of South China…. Hauptthemen laut MEDLINE: Neoplasms, Membrane Proteins, Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Health Research Project of Hunan Provincial Health Commission.
Abstract (Originalsprache)
PKMYT1 has emerged as a promising therapeutic target distinguished by its tumor‐selective expression and essential role in replication stress management. Unlike WEE1, PKMYT1 is dispensable in normal cell cycles but critical for cancer cells coping with DNA damage, establishing a broad therapeutic window. This vulnerability is exemplified by synthetic lethality in CCNE1‐amplified and TP53‐deficient contexts, where PKMYT1 inhibition triggers catastrophic mitotic entry. Beyond canonical cell cycle regulation, PKMYT1 functions as a multifaceted oncoprotein modulating signaling networks, metabolic reprogramming, and immune evasion via cGAS‐STING activation. With selective inhibitors like lunresertib (RP‐6306) now in Phase I/II trials, often combined with ATR inhibitors or chemotherapy, the field stands at a translational inflection point. However, context‐dependent roles (e.g., tumor‐suppressive functions in LUAD) and undefined resistance mechanisms pose challenges. This review critically evaluates PKMYT1's mechanistic underpinnings, clinical landscape, and biomarker strategies. We advocate for precision targeting based on genetic signatures (CCNE1, TP53, ER) to optimize therapeutic efficacy and overcome resistance in replication stress‐high malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Translational Medicine Institute, the Affiliated Chenzhou Hospital, Hengyang Medical School, University of South China, Chenzhou, China.
ORCID-Profile: Rongzhang He
Förderung
- The Health Research Project of Hunan Provincial Health Commission
Zitieren
APA
Li, L., He, B., Hao, M., Liu, Y., Song, S., & He, R. (2026). PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context‐Dependent Therapeutic Vulnerability. Genes, Chromosomes and Cancer, 65(7). https://doi.org/10.1002/gcc.70151
Vancouver
Li L, He B, Hao M, Liu Y, Song S, He R. PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context‐Dependent Therapeutic Vulnerability. Genes, Chromosomes and Cancer. 2026;65(7). doi:10.1002/gcc.70151
BibTeX
@article{Li2026,
author = {Li, Lingxi and He, Binfan and Hao, Mengmeng and Liu, Ye and Song, Shunxin and He, Rongzhang},
title = {PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context‐Dependent Therapeutic Vulnerability},
journal = {Genes, Chromosomes and Cancer},
year = {2026},
volume = {65},
number = {7},
doi = {10.1002/gcc.70151}
}
EUVIMED